Levetiracetam Noridem

Levetiracetam, the active ingredient in Levetiracetam Noridem, is an anticonvulsant presented as an intravenous solution for intravenous use. It is employed to control partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy. It is indicated for use in adult and pediatric populations as appropriate, and is administered under medical supervision.

GNH USA supplies Levetiracetam Noridem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice standards and provides regulatory documentation to support import and clinical use.

Levetiracetam is an antiepileptic medication that modulates neuronal excitability and is used in the management of several seizure types.

- Partial seizures: provides effective seizure control by markedly decreasing the frequency, duration, and intensity of focal epileptic events, thereby improving patient stability. - Generalized tonic‑clonic seizures: helps prevent full‑body convulsive episodes, reducing the risk of injury and contributing to overall seizure burden reduction in patients with generalized epilepsy. - Myoclonic seizures: reduces rapid, involuntary muscle jerks, lessening disruption of daily activities and enhancing functional ability and quality of life for individuals with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or urge to vomit. - Somnolence: increased sleepiness or drowsiness.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention. - Psychiatric changes: new or worsening depression, anxiety, or suicidal thoughts. - Blood disorders: thrombocytopenia or neutropenia observed in laboratory tests. - Rash with systemic involvement: Stevens‑Johnson syndrome rare but reported. - Anaphylaxis: life‑threatening hypersensitivity reaction. - Hepatic dysfunction: abnormal liver enzymes indicating possible liver injury.

When using levetiracetam, clinicians should consider several precautionary measures to ensure safe administration. - Renal function: adjust dose in patients with impaired renal clearance. - Pregnancy: use only if benefit outweighs risk; category B but monitor fetal development. - Concomitant CNS depressants: observe for enhanced sedation or dizziness. - Mood changes: monitor for depression, anxiety, or suicidal ideation. - Hypersensitivity: discontinue if rash, angioedema, or anaphylaxis occurs. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing effectiveness. - Phenobarbital: may increase clearance of levetiracetam, potentially compromising seizure control.

Moderate Interactions (Monitor Closely): - Opioids: additive CNS depression may increase dizziness or somnolence. - Antidepressants (SSRIs): may enhance risk of mood alterations. - Alcohol: combined use can exacerbate sedation and coordination impairment.